Author Archives: admin

Biostem U.S., Corporation Continues Building Its Scientific and Medical Board of Advisors With Appointment of Leading …

By adminMarch 19, 2012Uncategorized

CLEARWATER, FL--(Marketwire -03/19/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK - News) (Pinksheets: BOSM.PK - News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of Perinatologist Sanford M. Lederman, MD to its Scientific and Medical Board of Advisors (SAMBA).

As Chairman of the Department of Obstetrics and Gynecology at New York Methodist Hospital in Brooklyn, Dr. Lederman is consistently recognized by New Yorker Magazine's list of "Top Doctors" in New York. A specialist in high-risk pregnancy issues, Dr. Lederman has authored a number of scientific papers and is a highly regarded public speaker. He adds a very important dimension to the Biostem Scientific and Medical Board of Advisors by bringing specialized knowledge regarding the potential use of stem cell applications for the health of women and children.

Biostem President Dwight Brunoehler said, "Dr. Lederman is one of the most highly respected Obstetric and Gynecological physicians in the country. Sandy and I have worked together very actively on stem cell projects for over 18 years, including setting up a cord blood stem cell national donation system where all expectant moms have a chance to donate their baby's cord blood to benefit others."

Dr. Lederman stated, "Biostem's expansion plans mesh well with my personal interest in developing and advancing the use of non-controversial stem cells to improve the health of women and children. I have a particular interest in increasing the use of cord blood stem cells for in-utero transplant procedures, where stem cells are used to cure a potential life threatening disease such as sickle cell or thalassemia and other selective genetic disorders in a baby before it is even born."

Prior to accepting his current position with New York Methodist Hospital, Dr. Lederman was Residency Program Director and Vice Chairman of the Department of Obstetrics and gynecology at Long Island College Hospital in Brooklyn. At various times, he has served as a partner at Brooklyn Women's Health Care, President at Genetics East and Clinical Associate Professor at the State University of New York. He has served on the medical advisory board of several companies. He previously was Medical Director of Women's Health USA and was a founding member of the Roger Freeman Perinatal Society.

A graduate of Hunter College in New York, he received his initial medical training at Universidad Autonoma de Guadalajara School of Medicine. His initial internship was at New York Medical College in the Bronx. During the course of his career, Dr. Lederman has served and studied in various capacities at Long Island College Hospital in the Bronx, North Shore University Hospital in New York, Kings County Medical Center in Brooklyn, Long Beach Memorial Medical Center in California and the University of California at Irvine.

About Biostem U.S., CorporationBiostem U.S., Corporation (OTCQB: BOSM.PK - News) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered around providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through http://www.biostemus.com, or by calling Kerry D'Amato, Marketing Director at 727-446-5000.

The rest is here:
Biostem U.S., Corporation Continues Building Its Scientific and Medical Board of Advisors With Appointment of Leading ...

Stem cell therapy banned in Kuwait

By adminMarch 19, 2012Uncategorized

(MENAFN - Arab Times) Ministry of Health (MoH) employees holding PhD degrees announced that they will participate in the sit-in demonstration carried out by the Labor Union of Health Ministry, reports Al-Seyassah daily.

In the press release, they said they are protesting against the fact that they are receiving the same salary scale and benefits as any other ministry employee with lower qualifications and if necessary, they are ready to even burn their PhD certificates at the sit-in to get the benefits they deserve according to their qualifications.

The sit-in will be carried out in front of Health Ministry headquarters in Sulaibikhat at 10 am on Tuesday, March 20, 2012.

The number of PhD holders has exceeded 100 considering the participation of PhD holders from other ministries as well.

Meanwhile, the MoH has banned stem cell therapy in the country until the committee tasked to set the standards for the treatment completes its work, reports Al-Anba daily quoting Director of Health License Department Dr Marzouq Al-Bader.

Al-Bader disclosed the ministry had earlier formed the committee to ensure the stem cell procedures are carried out in an appropriate manner to protect the patients. He added the ministry will also issue a decision soon to regulate the use of antibiotics in the private health sector.

Meanwhile, Al-Bader confirmed the ministry has endorsed around 51,000 female doctors in private hospitals and health centers. He said the ministry closely monitors the performance of female doctors and those found to have violated the law will be referred to the Medical Council for the necessary action.

On the issuance of licenses through the Internet, Al-Bader revealed his department has asked the ministry to activate the e-link system for this purpose.

He said the ministry has asked the Kuwait Municipality to issue permit for the construction of a building fit for the department's operations.

Meanwhile, the Medical Emergency Department at the Ministry of Health has affirmed its readiness to deal with emergency cases that may arise due to a series of dust storms engulfing the country.

Visit link:
Stem cell therapy banned in Kuwait

RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster

By adminMarch 19, 2012Stem Cell Treatment

NOKOMIS, Fla.--(BUSINESS WIRE)--

As global demand for innovative new stem-cell therapies grows by the day, Rainbow BioSciences (OTCBB:RBCC.OB - News) new agreement with n3D Biosciences could help to bring these therapies to market faster than ever before.

Stem cell therapies are becoming increasingly important to healthcare advancement around the world. Rising care delivery costs, worldwide population aging, and potential physician shortages are only three of the issues facing world healthcare providers. The cost to bring a new drug to market has soared to $1.3 billion, and there are now half as many drugs seeking approval as there were 15 years ago.

Rising costs and potential shortages have led to a boom in demand for stem cell therapies. These advanced treatments could soon help to ease costs and provide effective disease treatment, potentially improving patient outcomes and reducing health care costs. For that to happen, however, real challenges must be overcome. Translation of these therapies from the lab to the clinic is slow, and widespread implementation could be a decade away or more.

Thanks to n3Ds Bio-Assembler technology, however, the development timeline for many stem cell therapies could potentially be shortened significantly. The Bio-Assembler enables researchers to culture cells in three dimensions faster and more easily than ever before, streamlining testing and research.

On Thursday, RBCC announced the acquisition of an equity interest in n3D, a fully commercialized company with plans to sell the ground-breaking Bio-Assembler to labs and researchers all over the world. RBCC expects n3Ds value to grow considerably as word spreads about the game-changing technology.

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ:CELG),Cardinal Health, Inc.(NYSE:CAH), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY).

About Rainbow BioSciences

See the original post:
RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster

Hometownstations.com-WLIO- Lima, OH News Weather SportsCalifornia's stem cell agency ponders its future

By adminMarch 19, 2012Stem Cell Clinic

By ALICIA CHANG AP Science Writer

LOS ANGELES (AP) - The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions.

The taxpayer-funded institute wielded the extraordinary power to dole out $3 billion in bond proceeds to fund embryonic stem cell work with an eye toward treatments for a host of crippling diseases. Midway through its mission, with several high-tech labs constructed, but little to show on the medicine front beyond basic research, the California Institute for Regenerative Medicine faces an uncertain future.

Is it still relevant nearly eight years later? And will it still exist when the money dries up?

The answers could depend once again on voters and whether they're willing to extend the life of the agency.

Several camps that support stem cell research think taxpayers should not pay another cent given the state's budget woes.

"It would be so wrong to ask Californians to pony up more money," said Marcy Darnovsky of the Center for Genetics and Society, a pro-stem cell research group that opposed Proposition 71, the state ballot initiative that formed CIRM.

Last December, CIRM's former chairman, Robert Klein, who used his fortune and political connections to create Prop 71, floated the possibility of another referendum.

CIRM leaders have shelved the idea of going back to voters for now, but may consider it down the road. The institute recently submitted a transition plan to Gov. Jerry Brown and the Legislature that assumes it will no longer be taxpayer-supported after the bond money runs out. CIRM is exploring creating a nonprofit version of itself and tapping other players to carry on its work.

"The goal is to keep the momentum going," board Chairman Jonathan Thomas said in an interview.

Link:
Hometownstations.com-WLIO- Lima, OH News Weather SportsCalifornia's stem cell agency ponders its future

California's stem cell agency ponders a future without taxpayer support

By adminMarch 19, 2012Uncategorized

LOS ANGELES, Calif. - The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions.

Is it still relevant nearly eight years later? And will it still exist when the money dries up?

The answers could depend once again on voters and whether they're willing to extend the life of the agency.

Several camps that support stem cell research think taxpayers should not pay another cent given the state's budget woes.

Last December, CIRM's former chairman, Robert Klein, who used his fortune and political connections to create Prop 71, floated the possibility of another referendum.

CIRM leaders have shelved the idea of going back to voters for now, but may consider it down the road. The institute recently submitted a transition plan to Gov. Jerry Brown and the Legislature that assumes it will no longer be taxpayer-supported after the bond money runs out. CIRM is exploring creating a non-profit version of itself and tapping other players to carry on its work.

"The goal is to keep the momentum going," board Chairman Jonathan Thomas said in an interview.

So far, CIRM has spent some $1.3 billion on infrastructure and research. At the current pace, it will earmark the last grants in 2016 or 2017. Since most are multi-year awards, it is expected to stay in business until 2021.

Continue reading here:
California's stem cell agency ponders a future without taxpayer support

California's stem cell agency ponders its future

By adminMarch 19, 2012Uncategorized

LOS ANGELES (AP) The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions.

Is it still relevant nearly eight years later? And will it still exist when the money dries up?

The answers could depend once again on voters and whether they're willing to extend the life of the agency.

Several camps that support stem cell research think taxpayers should not pay another cent given the state's budget woes.

Last December, CIRM's former chairman, Robert Klein, who used his fortune and political connections to create Prop 71, floated the possibility of another referendum.

"The goal is to keep the momentum going," board Chairman Jonathan Thomas said in an interview.

View post:
California's stem cell agency ponders its future

Stem cell brain injections ease Parkinson's

By adminMarch 18, 2012Stem Cell Treatment

MONKEYS with Parkinson's disease-like symptoms have had their suffering eased by an injection of human embryonic stem cells (hESCs) into their brain.

Jun Takahashi of Kyoto University in Japan and colleagues injected these cells into monkeys whose brains had been damaged by a chemical that destroys dopamine-producing neurons and so causes Parkinson's symptoms.

Two monkeys received hESCs that had been matured into an early form of neural cell. Six months later, the monkeys had recovered 20 to 45 per cent of the movement they had lost before treatment. Post-mortems a year after treatment showed that the cells had developed into fully functioning dopamine-secreting neurons. Another monkey that received less-mature neural cells also showed improvements (Stem Cells, DOI: 10.1002/stem.1060).

"Monkeys starting with tremors and rigidity [began] to move smoothly, and animals originally confined to sitting down were able to walk around," says Takahashi.

The team says it will probably be four to six years before clinical trials in humans begin.

If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.

Only subscribers may leave comments on this article. Please log in.

Only personal subscribers may leave comments on this article

Subscribe now to comment.

All comments should respect the New Scientist House Rules. If you think a particular comment breaks these rules then please use the "Report" link in that comment to report it to us.

See the rest here:
Stem cell brain injections ease Parkinson's

Stem Cell Transplant Keeps Hope Alive

By adminMarch 17, 2012Stem Cell Clinic

Memphis, Tn - Jana Stressel and her husband Jay were living life as empty nesters. She was active and healthy, walking five miles a day. The couple was getting ready for an out of town trip back in 2009, when sickness settled in. Jay knew it was trouble so he rushed his wife of 28 years to the hospital.

"They immediately sensed something was wrong. My blood pressure was really high. I was in bad shape...they went to work on me very quickly," says Jana.

Doctors told Jana she was losing blood from somewhere, so she underwent several blood transfusions. Her kidneys were shutting down. For two weeks, doctors wondered what was going on. Doctor Ed Muir, an oncologist with the Jones clinic, was the doctor who finally diagnosis her.

"He came in and told us I had multiple myeloma."

The cancer was at stage 3, which means the disease was already advanced. To make matters worse, she had kidney dysfunction, which required dialysis. She started chemotherapy the next day.

"My cancer is aggressive so they have to treat it aggressively, and there have been some pretty bad days."

At one point, she was receiving 3 different chemotherapy treatments at one time.

"I never cried, I was never sad, I was never scared. I just pretty much felt like ok, what do I need to go? Let's do it."

Dr. Muir explains Multiple Myeloma as cancer of the plasma cells in the bone marrow. The plasma cells grow out of control and form tumors in the areas of solid bone.

The growth of the bone tumors make it harder for the bone marrow to make healthy blood cells. This makes a person more prone to infections, back pain, fatigue, and unexplained broken bones, all symptoms Jana had, but ignored.

Read the rest here:
Stem Cell Transplant Keeps Hope Alive

Eastday-Big stem cell breakthrough

By adminMarch 17, 2012Stem Cell Treatment

A NEW stem cell therapy treatment to develop new bones for patients with bone loss and new skin for recipients of plastic surgery has been developed, doctors from Shanghai No.9 People's Hospital announced yesterday.

In the procedure, medical staff use a special machine to collect stem cells from a patient's blood. The stem cells adhere to a base made of a special biological material.

The stem cells are then transplanted into the patient's body, where they grow into either new bones or skin tissue, while the base is absorbed by the human body.

"So far the practice has been successful in treating patients with bone and skin loss," said Dr Dai Kerong from Shanghai Jiao Tong University's translational medicine institute at Shanghai No.9 hospital. "The stem cell technology will be used to develop corneas for blind people as well as treating heart attack and stroke patients by developing new heart and cerebral tissue."

The technology is patented in China and abroad and will be licensed within one or two years, according to Dai.

China has established 51 translational medicine centers to boost the introduction of laboratory research into clinical use.

The complicated procedures and documentation required often prevent doctors from introducing lab success into clinical practice.

Dai said one reagent developed by No. 9 hospital's doctors for in vitro fertilization received a license in Europe within six months and has been used in clinical practice "while this would take at least five years in China."

Read this article:
Eastday-Big stem cell breakthrough

Gov. Perry's stem-cell firm draws FDA scrutiny

By adminMarch 16, 2012Stem Cell Medicine

The U.S. Food and Drug Administration has received a complaint alleging the Houston company involved in Gov. Rick Perry's unregulated adult stem-cell operation is a potential danger to patients and not in compliance with federal law.

In an eight-page letter sent last month, University of Minnesota bioethicist Leigh Turner called on the FDA to investigate Celltex Therapeutics Corp., which banks people's stem cells for future reinjection in the event of disease or injury. Perry was the company's first customer last year.

"It appears their business plan involves injecting or infusing on a for-profit, commercial basis non-FDA-approved adult stem cells into paying customers," Turner wrote in the Feb. 21 letter. "This plan conflicts with FDA regulations governing human stem cells."

An FDA spokeswoman declined comment, but Turner said an agency official told him the matter has been assigned to an investigator and is being taken seriously.

Celltex co-founder David Eller said Tuesday night he is confident the company will "meet all FDA specifications." He emphasized that Celltex doesn't administer stem cells, but stores and processes them at the behest of doctors who later reinject them into patients.

Dr. Stanley Jones, a Houston orthopedic surgeon, injected Perry's stem cells during his back surgery in July.

The plan by Celltex and Perry to make Texas a leader in the therapy have been controversial since details about the governor's procedure became known last summer. The therapy, drawing on the ability of adult stem cells to replenish dying cells, is promising but thought by most medical researchers to need much more clinical study before it is commercialized.

Stem cells are a kind of medicine known as biologics, therapy involving living cells rather than chemicals. Most medical experts say that adult stem-cell therapy involves more than the "minimal manipulation" the agency allows without its oversight because the cells are isolated, cultured in a laboratory and stored for some period of time before being reinjected.

The FDA has recently stepped up enforcement of unregulated adult stem cell activity, though legal experts interviewed last fall by the Chronicle said it was unclear whether the agency would look into Perry's procedure because he seemed fully informed and unharmed by it.

The Texas Medical Board is currently considering a policy that would require providers of stem cells and other experimental drugs to use them only with the permission of independent review committees that assess trials for patient safety. The policy comes up for final approval in April.

Continued here:
Gov. Perry's stem-cell firm draws FDA scrutiny